Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification

Hepatology

Volumn 60, Issue 6, 2014, Pages 1972-1982

  Ahn, Sung Min ^a   Jang, Se Jin ^a   Shim, Ju Hyun ^a   Kim, Deokhoon ^a   Hong, Seung Mo ^a   Sung, Chang Ohk ^a   Baek, Daehyun ^b   Haq, Farhan ^a,c   Ansari, Adnan Ahmad ^a,c   Lee, Sun Young ^a   Chun, Sung Min ^a   Choi, Seongmin ^b   Choi, Hyun Jeung ^a   Kim, Jongkyu ^b   Kim, Sukjun ^b   Hwang, Shin ^a   Lee, Young Joo ^a   Lee, Jong Eun ^d   Jung, Wang Rim ^d   Jang, Hye Yoon ^e   Yang, Eunho ^d   Sung, Wing Kin ^e,f   Lee, Nikki P ^g   Mao, Mao ^h   Lee, Charles ⁱ   Zucman Rossi, Jessica ^j,k,l   Yu, Eunsil ^a   Lee, Han Chu ^a   Kong, Gu ^m   more..

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Gachon University College of Medicine   (South Korea)

^d DNA Link Inc   (South Korea)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f GENOME INSTITUTE OF SINGAPORE   (Singapore)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

^h Translational Bioscience and Diagnostics WeXi App Tec Co Ltd   (China)

ⁱ Jackson Laboratory for Genomic Medicine   (United States)

^j INSERM   (France)

^k UNIVERSITÉ PARIS DESCARTES   (France)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^m Hanyang University   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

E2F1 PROTEIN, HUMAN; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; TUMOR MARKER;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COPY NUMBER VARIATION; FEMALE; GENETICS; HUMAN; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; E2F1 TRANSCRIPTION FACTOR; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84901472677     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27198     Document Type: Article

References (30)

1. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 2013;58:1693-1702.
2. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012;44:760-764.
3. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012;44:694-698.
4. Huang J, Deng Q, Wang Q, Li K-Y, Dai J-H, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012.
5. Jiang Z, Jhunjhunwala S, Liu J, Haverty PM, Kennemer MI, Guan Y, et al. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res 2012;22:593-601.
6. Kan Z, Zheng H, Liu X, Li S, Barber T, Gong Z, et al. Whole genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013;23:1422-1433.
7. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011;43:828-829.
8. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
9. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
10. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009;16:453-463.
11. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
12. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
13. Larson NB, Fridley BL. PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing data. Bioinformatics 2013;29:1888-1889.
14. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15-20.
15. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-293.
16. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013.
17. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012;22:568-576.
18. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-1303.
19. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013 [Epub ahead of print].
20. Gorgoulis VG, Zacharatos P, Kotsinas A, Mariatos G, Liloglou T, Vogiatzi T, et al. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs). Mol Med 2000;6:208-237.
21. Sawey Eric T, Chanrion M, Cai C, Wu G, Zhang J, Zender L, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011;19:347-358.
22. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-428.
23. Kim K-A, Wagle M, Tran K, Zhan X, Dixon MA, Liu S, et al. R-Spondin family members regulate the Wnt pathway by a common mechanism. Mol Biol Cell 2008;19:2588-2596.
24. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006;243:229-235.
25. Sasaki Y, Yamada T, Tanaka H, Ohigashi H, Eguchi H, Yano M, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006;244:771-780.
26. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000;14:2393-2409.
27. Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang ZY, et al. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology 2011;140:1063-1070.
28. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007;26:2166-2176.
29. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003;23:405-409.
30. Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007;26:774-780.